T1International, an advocacy group for type 1 diabetics, is calling on pharmaceutical companies like Eli Lilly to lower their insulin prices. The group has been pushing these efforts in Indianapolis for several years.

A recently approved economic package will lower out-of-pocket costs for some patients. Many who rely on the costly medication say the measure doesn't go far enough.

The new price -- starting Jan. 1 -- will be about $80 per vial and comparable to how much a vial of Lilly's brand name Humalog insulin cost in 2008.

Starting Jan. 1, Lilly will drop the cost of its Insulin Lispro Injection -- the generic of its insulin Humalog -- by 40 percent, saving about $50 per vial.

In Indiana, hundreds of thousands of people lack easy access to grocery stores. Many more can't afford to buy healthy food, and that's a problem for anyone with diabetes.

The pandemic has left millions of Americans without jobs -- and health insurance. And for the one in 10 Americans with diabetes, this poses a life-threatening problem. Now, many are scrambling to pay for their insulin.

Inconsistent delivery of diabetes medications was commonly reported, and prisoners say the pandemic has strained an already strapped health care system in the state prisons.

The Lilly Insulin Value Program covers most insulins made by the drug maker and is available to those with or without insurance.

After a report criticized Eli Lilly and Co. for not doing enough to make affordable insulin available, the company launched a campaign Thursday to raise awareness of their discount options.

The Lawrence Township school district says it's working closely with Community Health Network "to determine the cause of the error."